Literature DB >> 15315791

Factors associated with the performance of carrier erythrocytes obtained by hypotonic dialysis.

Carmen Gutiérrez Millán1, Aránzazu Zarzuelo Castañeda, Ma Luisa Sayalero Marinero, José M Lanao.   

Abstract

Carrier erythrocytes containing drugs, enzymes or peptides can be used as a delivery system that allows changes in the kinetic behaviour and selective biodistribution of the substances encapsulated. Hypotonic dialysis is the method most commonly used in the preparation of carrier erythrocytes, but many factors affect the yield and characteristics of the ghost erythrocytes obtained using this method. This review analyses the factors that affect the performance of carrier erythrocytes prepared by hypotonic dialysis. Factors such as the composition and osmolality range of the hypotonic buffer used, the duration of the hypotonic dialysis, temperature, the volume ratio between the erythrocyte suspension and the dialysis buffer, the inclusion in the process of an annealing phase, the composition and osmolality of the resealing buffer, and the conditions under which the final washing of the erythrocytes is carried out may all affect the morphological properties and the later in vivo behaviour of the ghost erythrocytes obtained. Changes in the yield of the encapsulation process, the in vitro drug or enzyme controlled delivery, the pharmacokinetic properties or the in vivo tissue targeting may be modified depending on the conditions under which the preparation of carrier erythrocytes by hypotonic dialysis is carried out. Chemical alterations to the membrane of carrier erythrocytes obtained by hypotonic dialysis with substances such as glutaraldehyde, band 3 cross-linking reagents, trypsin or NHS-biotin, among others, may affect the release rate of the substances encapsulated and may increase the uptake of cells by macrophages both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15315791     DOI: 10.1016/j.bcmd.2004.06.004

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  14 in total

1.  The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors.

Authors:  Mukaddes Izci; Christy Maksoudian; Bella B Manshian; Stefaan J Soenen
Journal:  Chem Rev       Date:  2021-01-14       Impact factor: 60.622

Review 2.  Re-Engineering Extracellular Vesicles as Smart Nanoscale Therapeutics.

Authors:  James P K Armstrong; Margaret N Holme; Molly M Stevens
Journal:  ACS Nano       Date:  2017-01-09       Impact factor: 15.881

3.  Engineering of erythrocyte-based drug carriers: control of protein release and bioactivity.

Authors:  Rongcong Luo; Shaillender Mutukumaraswamy; Subbu S Venkatraman; Björn Neu
Journal:  J Mater Sci Mater Med       Date:  2011-11-18       Impact factor: 3.896

4.  Drug-loaded sickle cells programmed ex vivo for delayed hemolysis target hypoxic tumor microvessels and augment tumor drug delivery.

Authors:  Se-woon Choe; David S Terman; Angela E Rivers; Jose Rivera; Richard Lottenberg; Brian S Sorg
Journal:  J Control Release       Date:  2013-07-18       Impact factor: 9.776

Review 5.  A novel strategy to achieve effective drug delivery: exploit cells as carrier combined with nanoparticles.

Authors:  Liang Pang; Chun Zhang; Jing Qin; Limei Han; Ruixiang Li; Chao Hong; Huining He; Jianxin Wang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

6.  Newly engineered magnetic erythrocytes for sustained and targeted delivery of anti-cancer therapeutic compounds.

Authors:  Caterina Cinti; Monia Taranta; Ilaria Naldi; Settimio Grimaldi
Journal:  PLoS One       Date:  2011-02-23       Impact factor: 3.240

7.  Characterization of human erythrocytes as potential carrier for pravastatin: an in vitro study.

Authors:  Gamal El-din I Harisa; Mohamed F Ibrahim; Fars K Alanazi
Journal:  Int J Med Sci       Date:  2011-03-11       Impact factor: 3.738

8.  Erythrocyte G protein as a novel target for malarial chemotherapy.

Authors:  Sean C Murphy; Travis Harrison; Heidi E Hamm; Jon W Lomasney; Narla Mohandas; Kasturi Haldar
Journal:  PLoS Med       Date:  2006-12       Impact factor: 11.069

Review 9.  Cell or cell membrane-based drug delivery systems.

Authors:  Songwei Tan; Tingting Wu; Dan Zhang; Zhiping Zhang
Journal:  Theranostics       Date:  2015-04-27       Impact factor: 11.556

Review 10.  Bio-Nanocarriers for Lung Cancer Management: Befriending the Barriers.

Authors:  Shruti Rawal; Mayur Patel
Journal:  Nanomicro Lett       Date:  2021-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.